**The Authors Reply**We appreciate the interest of Dr. Imamura in our recent paper, as well as his valuable comments ([@B1]). In our study, hypoalbuminemia was defined as a serum albumin level of ≤3.4 g/dL because the median serum albumin level was 3.4 g/dL, which is generally accepted as the cutoff value ([@B2]-[@B4]). In response to Dr. Imamura\'s initial comment, we performed a receiver-operating characteristic (ROC) curve analysis, and 3.8 g/dL was found to be the ideal cutoff value for predicting the outcome in our dataset. However, hypoalbuminemia at admission, defined as a serum albumin level of ≤3.8 g/dL, was not associated with the long-term outcomes \[hazard ratio (HR), 1.21; 95% confidence interval (CI), 0.70-2.22; p=0.511 in the pre-match model, and HR, 0.97; 95% CI, 0.45-2.07; p=0.934 in the post-match model\].

The duration of follow-up varied across individual cases on the basis of the relatively long enrollment period (i.e., 5 years) and thus the numbers at risk decreased with the passage of time. In the Kaplan-Meier survival analyses, the two curves crossed after several years, as Dr. Imamura pointed out. However, the proportional hazards assumption was confirmed in both the pre-match and post-match models using log-minus-log survival graphs. It is often difficult to show the relationship between parameters/conditions in the acute phase and the long-term outcomes. However, many reports have investigated the relationships between parameters/conditions in the acute phase and long-term outcomes ([@B5],[@B6]). Again, we thank Dr. Imamura for his interest and comments on our paper.
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